WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524718
CAS#: 126661-07-2
Description: CI 951 is a novel dihydronaphthyridine Ca2+ antagonist, channel blocker. CI-951 may be a useful therapeutic agent for focal cerebral ischemia. It has potential as a cerebral vasodilator.
Hodoodo Cat#: H524718
Name: CI 951
CAS#: 126661-07-2
Chemical Formula: C22H23F3N2O3
Exact Mass: 420.17
Molecular Weight: 420.420
Elemental Analysis: C, 62.85; H, 5.51; F, 13.56; N, 6.66; O, 11.42
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CI 951; CI-951; CI951.
IUPAC/Chemical Name: 1,6-Naphthyridine-3-carboxylic acid, 1,4-dihydro-2-methyl-5-(1-methylethoxy)-4-(2-(trifluoromethyl)phenyl)-, ethyl ester
InChi Key: XVXQOAYCEUDQTQ-SFHVURJKSA-N
InChi Code: InChI=1S/C22H23F3N2O3/c1-5-29-21(28)17-13(4)27-16-10-11-26-20(30-12(2)3)19(16)18(17)14-8-6-7-9-15(14)22(23,24)25/h6-12,18,27H,5H2,1-4H3/t18-/m0/s1
SMILES Code: N1C(=C([C@@H](c2c(nccc12)OC(C)C)c1c(cccc1)C(F)(F)F)C(=O)OCC)C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 420.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Knight WA, Hart KW, Adeoye OM, Bonomo JB, Keegan SP, Ficker DM, Szaflarski JP, Privitera MD, Lindsell CJ. The incidence of seizures in patients undergoing therapeutic hypothermia after resuscitation from cardiac arrest. Epilepsy Res. 2013 Oct;106(3):396-402. doi: 10.1016/j.eplepsyres.2013.06.018. Epub 2013 Jul 29. PubMed PMID: 23906560; PubMed Central PMCID: PMC3961478.
2: Papadakaki M, Tzamalouka GS, Chatzifotiou S, Chliaoutakis J. Seeking for risk factors of Intimate Partner Violence (IPV) in a Greek national sample: the role of self-esteem. J Interpers Violence. 2009 May;24(5):732-50. doi: 10.1177/0886260508317181. Epub 2008 May 7. PubMed PMID: 18463309.
3: Koike K, Takayanagi I, Takiguchi S, Urita Y, Miyake N. Ca-blocking action of stereoisomers of CI-951, (+)-CI-951 (NC-1500) and (-)-CI-951 in the isolated muscle preparations. Gen Pharmacol. 1992 Mar;23(2):207-10. PubMed PMID: 1639233.
4: Pucilowski O, Rezvani AH, Janowsky DS. Suppression of alcohol and saccharin preference in rats by a novel Ca2+ channel inhibitor, Goe 5438. Psychopharmacology (Berl). 1992;107(2-3):447-52. PubMed PMID: 1615142.
5: Meyer FB, Anderson RE, Sundt TM Jr. The novel dihydronaphthyridine Ca2+ channel blocker CI-951 improves CBF, brain pHi, and EEG recovery in focal cerebral ischemia. J Cereb Blood Flow Metab. 1990 Jan;10(1):97-103. PubMed PMID: 2298840.